Optimizing Dosing Strategies in Oral Iron Supplementation

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to evaluate, if a change in dosing strategy in oral iron supplementation from leads to an improvement of iron absorption and consequently a faster therapy in patients with iron deficiency. The main question the study aims to answer is: Does a treatment effect (measured by change in hemoglobin after 12 weeks of treatment) exist between daily oral iron supplementation and interval administration (every second day)? Participants will receive oral iron supplementation every second day with double the standard dose (intervention group). Researchers will compare this group with the active control group, that receives oral iron supplementation every day with the standard dose. Participants will present for three patient visits (at baseline, after 6 and after 12 weeks of treatment).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Informed Consent signed by the subject

• ≥18 years of age

• Iron deficiency: Ferritin \<30 µg/l

• hemoglobin ≥ 80 g/l

• CRP \< 5 mg/l

Locations
Other Locations
Switzerland
Luzerner Kantonsspital
RECRUITING
Lucerne
Contact Information
Primary
Meyer
eisenstudie@luks.ch
+41 41 205 11 11
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 100
Treatments
Experimental: Intervention Group
Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every second day 2 x 80 mg Tardyferon® for a duration of 12 weeks.
Active_comparator: Active Control
Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every day 1x 80 mg Tardyferon® for a duration of 12 weeks
Related Therapeutic Areas
Sponsors
Leads: Luzerner Kantonsspital

This content was sourced from clinicaltrials.gov